Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Wave Life Sciences Ltd. before investing.

In this article, we go over a few key elements for understanding Wave Life Sciences Ltd.’s stock price such as:

• Wave Life Sciences Ltd.’s current stock price and volume
• Why Wave Life Sciences Ltd.’s stock price changed recently
• Upgrades and downgrades for WVE from analysts
• WVE’s stock price momentum as measured by its relative strength

About Wave Life Sciences Ltd. (WVE)

Before we jump into Wave Life Sciences Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Want to learn more about Wave Life Sciences Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Wave Life Sciences Ltd..

Wave Life Sciences Ltd.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Wave Life Sciences Ltd.’s stock price was $7.670.

Wave Life Sciences Ltd. is up 3.23% from its previous closing price of $7.430.

During the last market session, Wave Life Sciences Ltd.’s stock traded between $7.405 and $7.720. Currently, there are approximately 167.74 million shares outstanding for Wave Life Sciences Ltd..

Wave Life Sciences Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Wave Life Sciences Ltd. Stock Price History

Wave Life Sciences Ltd.’s (WVE) price is currently down 15.15% so far this month.

During the month of November, Wave Life Sciences Ltd.’s stock price has reached a high of $9.130 and a low of $6.510.

Over the last year, Wave Life Sciences Ltd. has hit prices as high as $16.384 and as low as $5.280. Year to date, Wave Life Sciences Ltd.’s stock is down 38%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Wave Life Sciences Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were 2 analysts who downgraded Wave Life Sciences Ltd.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Wave Life Sciences Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Wave Life Sciences Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Wave Life Sciences Ltd.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Wave Life Sciences Ltd. (WVE) by visiting AAII Stock Evaluator.

Relative Price Strength of Wave Life Sciences Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Wave Life Sciences Ltd. has a weighted four-quarter relative price strength of -14.70%, which translates to a Momentum Score of 16 and is considered to be Very Weak.

Want to learn more about how Wave Life Sciences Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Wave Life Sciences Ltd. Stock Price: Bottom Line

As of November 26, 2025, Wave Life Sciences Ltd.’s stock price is $7.670, which is up 3.23% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Wave Life Sciences Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.